Back to Search
Start Over
Should we consider MMF therapy after rituximab for nephrotic syndrome?
- Source :
-
Pediatric Nephrology . Oct2011, Vol. 26 Issue 10, p1759-1762. 4p. - Publication Year :
- 2011
-
Abstract
- The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20-positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0931041X
- Volume :
- 26
- Issue :
- 10
- Database :
- Academic Search Index
- Journal :
- Pediatric Nephrology
- Publication Type :
- Academic Journal
- Accession number :
- 65075995
- Full Text :
- https://doi.org/10.1007/s00467-011-1894-x